Corbus Pharmaceuticals (CRBP) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Corbus Pharmaceuticals (NASDAQ:CRBP) released its earnings results on Thursday. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.05), MarketWatch Earnings reports. The firm had revenue of $1.09 million during the quarter, compared to analysts’ expectations of $1.66 million.

Shares of NASDAQ CRBP traded down $0.26 during trading hours on Friday, hitting $6.61. 942,460 shares of the company traded hands, compared to its average volume of 1,131,068. The company has a market cap of $435.91 million, a P/E ratio of -10.17 and a beta of 2.16. Corbus Pharmaceuticals has a 12 month low of $4.50 and a 12 month high of $9.95.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRBP. BlackRock Inc. grew its position in Corbus Pharmaceuticals by 31.7% in the 3rd quarter. BlackRock Inc. now owns 5,220,146 shares of the biopharmaceutical company’s stock valued at $39,412,000 after acquiring an additional 1,256,503 shares during the last quarter. IFP Advisors Inc grew its position in Corbus Pharmaceuticals by 12.0% in the 2nd quarter. IFP Advisors Inc now owns 1,500,805 shares of the biopharmaceutical company’s stock valued at $7,579,000 after acquiring an additional 160,250 shares during the last quarter. Northern Trust Corp grew its position in Corbus Pharmaceuticals by 7.6% in the 2nd quarter. Northern Trust Corp now owns 572,325 shares of the biopharmaceutical company’s stock valued at $2,890,000 after acquiring an additional 40,356 shares during the last quarter. Renaissance Technologies LLC bought a new position in Corbus Pharmaceuticals in the 2nd quarter valued at $842,000. Finally, Millennium Management LLC bought a new position in Corbus Pharmaceuticals in the 2nd quarter valued at $772,000. 42.69% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on CRBP shares. ValuEngine raised Corbus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 21st. BidaskClub downgraded Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 18th. Cantor Fitzgerald set a $36.00 target price on Corbus Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 1st. Finally, B. Riley started coverage on Corbus Pharmaceuticals in a research report on Wednesday, October 24th. They set a “buy” rating and a $22.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. Corbus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $27.33.

TRADEMARK VIOLATION NOTICE: This story was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/11/10/corbus-pharmaceuticals-crbp-releases-quarterly-earnings-results-misses-estimates-by-0-05-eps.html.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.

See Also: Diversification in Investing

Earnings History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply